Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tequatrovirus V1EC23 + Vectrevirus V1EC44
- Development stage
- Preclinical
- Lead developer
- Hospices Civils de Lyon
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Tequatrovirus V1EC23 + Vectrevirus V1EC44 is a synergistic bacteriophage combination being developed for the clearance of intestinal colonization by multidrug-resistant and carbapenemase-producing Escherichia coli ST131. The combination consists of two virulent phages: Tequatrovirus V1EC23 (TQV-V1EC23), which targets the outer membrane protein Tsx, and Vectrevirus V1EC44 (VCV-V1EC44), which targets the bacterial capsule. This dual-targeting mechanism provides complementary host range coverage and creates evolutionary trade-offs, where resistance to one phage increases sensitivity to the other, preventing the emergence of resistance and enabling effective eradication of E. coli ST131 colonization.
- Other names
- TQV-V1EC23 + VCV-V1EC44Tequatrovirus V1EC23 and Vectrevirus V1EC44
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)Tsx (Nucleoside-specific channel-forming protein Tsx)
Beyond the preview
Go deeper on Tequatrovirus V1EC23 + Vectrevirus V1EC44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tequatrovirus V1EC23 + Vectrevirus V1EC44.